key: cord-0705336-mb0ojtev
authors: Ross, Sydney B.; Wilson, Marnie Goodwin; Papillon‐Ferland, Louise; Elsayed, Sarah; Wu, Peter E.; Battu, Kiran; Porter, Sandra; Rashidi, Babak; Tamblyn, Robyn; Pilote, Louise; Downar, James; Bonnici, Andre; Huang, Allen; Lee, Todd C.; McDonald, Emily G.
title: COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults
date: 2020-05-22
journal: J Am Geriatr Soc
DOI: 10.1111/jgs.16623
sha: 5f95cfd3c783ec68273406cd6447455b4fcdd388
doc_id: 705336
cord_uid: mb0ojtev

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug–drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. OBJECTIVES: We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking which would interact with hydroxychloroquine. METHODS: We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug–drug interactions with hydroxychloroquine that might exclude them from participation in a typical coronavirus disease 2019 (COVID‐19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as being potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine. RESULTS: The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and anti‐diabetic agents. CONCLUSION: The COVID‐19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID‐19. This article is protected by copyright. All rights reserved.

The first cluster of cases of COVID-19 disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported to the World Health Organization on December 31 st , 2019. 1,2 On March 11 th , 2020 the World Health Organization declared COVID-19 a pandemic 3 and at the time of writing, greater than 4.3 million laboratory-confirmed cases have been documented globally, with greater than 290,000 related deaths. 4 In response, more than 600 interventional trials have been registered to investigate whether existing medications are safe and effective for the treatment of COVID-19 disease. 5 One class of medications that has demonstrated therapeutic properties in vitro are the antimalarial agents chloroquine and hydroxychloroquine. 6 Following results from the early emerging literature, including several small clinical trials [7] [8] [9] [10] , an uncontrolled case series 11 , and an open label non-randomized study from France 12 , the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for hydroxychloroquine for hospitalized patients with COVID-19 who are unable to participate in clinical trials. [13] [14] [15] These studies were heavily referenced in the media despite inconclusive data and trials for use as prophylaxis and treatment are ongoing. 12, 16 More recently, an observational study on hydroxychloroquine was published showing no improvement in clinical outcomes in patients hospitalized with COVID- 19 . 17 At the present time, the FDA and the Infectious Disease Society of America (IDSA) recommend against its use outside of clinical trials. 18 The results of randomized controlled trials are forthcoming and the medication may still be prescribed outside of a trial, for lack of any alternative treatment. This article is protected by copyright. All rights reserved.

One population in critical need of effective treatments for COVID-19 are older adults with comorbid conditions including diabetes, hypertension, and cardiac conditions. Studies suggest older adults are more susceptible to infection with COVID-19 and are at a higher risk of severe complications when compared to the general population. 19, 20 Outbreaks in long-term care facilities resulting in death have emphasized the vulnerability of this population. 21 With increasing age, there are higher rates of medical conditions observed, leading to a higher prevalence of polypharmacy (taking multiple medications); 22,23 as many as 56.7% of community dwelling North Americans over the age of 65 are taking five or more regular medications. 24, 25 Polypharmacy is harmful, given the association with falls, fractures, and other adverse drug events. 26 However, we are now encountering another problem from taking multiple medications: a substantial risk of drug-drug interactions with potential therapies for COVID- 19 . 27 Many of these interacting medications are potentially inappropriate medications (PIMs), which themselves carry an increased risk for adverse drug events (ADEs), and could be deprescribed (stopped, tapered or switched to a safer alternative). [28] [29] [30] [31] We hypothesized that due to polypharmacy and clinically significant drug-drug interactions, many older adults with their current drug regimens will be ineligible for COVID-19 therapeutic trials and/or treatment with medications that are currently under investigation, including, but not limited to, the antimalarial hydroxychloroquine. This despite older adults being at an increased risk of complications as a result of COVID-19 and representing a population most likely to benefit from different therapeutic options. We postulated that many of these drug-drug interactions are due to PIMs which could be deprescribed proactively. In light of a recent FDA warning regarding risk of QTc prolongation, we examined hydroxychloroquine 14 (as a test case) to estimate the prevalence of prescribed medications with drug-drug interactions in a cohort of hospitalized older adults with polypharmacy. We aimed to better characterize the burden of PIMs that could be deprescribed with the impetus being the COVID-19 pandemic.

The MedSafer Pilot study 32 was a large controlled before and after deprescribing trial that took place between September 2016 and May 2017 on 4 Canadian academic internal medicine clinical teaching units. The trial was designed to assess whether a computer-assisted medication review tool augmented the deprescribing of PIMs at discharge in a population of hospitalized older adults with polypharmacy. The software's algorithm identified PIMs and provided deprescribing recommendations for each individual patient by applying rules derived from widely available consensus documents for safer prescribing in older adults. 30, 31, 33 Details of the trial are described elsewhere. 32 Briefly, patients were identified on admission via the emergency room to one of the designated units after discussion with the treating team to see if the met they broad inclusion criteria of 65-years and older and taking five or more medications. Patient data concerning medical conditions, validated medications and some lab results were collected and entered into the MedSafer deprescribing electronic decision support software which identified PIMs through drug-disease combinations; drug-drug interactions; or those that should be avoided or used with caution in older adults. The

MedSafer system generated a report of the PIM, included a level of harm (high risk, intermediate risk, or low risk but little added value), the rationale for deprescribing and, when appropriate, a tapering protocol.

For the present study, we re-analyzed the MedSafer data as a representative sample of vulnerable older adults with polypharmacy. We first searched the literature for medications with known drug-drug interactions with hydroxychloroquine by examining the product monograph 34 , referring to drug-drug interaction websites 35, 36 , and reviewing the exclusion criteria for a currently enrolling FDA and Health Canada approved hydroxychloroquine trial for COVID-19 (NCT04308668). 5, 37, 38 Medications with known interactions with hydroxychloroquine were grouped according to the American Hospital Formulary Service (AHFS) classification 39 (Table 1 ) and divided into two categories: chronic medications and medications typically prescribed for a short course such as antibiotics. We analyzed all patients in the MedSafer study who consented to participate in the deprescribing trial and who had a complete medication reconciliation performed on admission. We theoretically 'exposed' this patient cohort to treatment with hydroxychloroquine (minimum 5-days at a minimum dose of 600mg daily as in NCT04308668) and identified possible drug interactions, as well as potential harmful outcomes such as increased toxicity of hydroxychloroquine, risk of QTc prolongation or malignant cardiac arrhythmia, or risk of other adverse drug events requiring closer monitoring during therapy such as severe hypoglycemia (Table 2) . From all interacting medications we ran the MedSafer algorithms to determine the proportion of medications that were PIMs and that could be deprescribed. We also identified the triggering condition associated with each PIM (e.g. atrial fibrillation, heart failure, dementia, delirium or renal failure). those that require monitoring if there is to be ongoing use, and medications that likely cannot be stopped due to risk of an adverse drug withdrawal event.

The MedSafer 32 cohort contained 1001 patients with complete data on their home medications. The median age of the cohort was 80 years and approximately 50% were women.

More than half had hypertension, approximately 40% had diabetes, and close to 50% were moderately to severely frail as defined by the Clinical Frailty Scale. 40 All patients were hospitalized in a tertiary care hospital and were admitted to one of four general medical wards in one of 3 Canadian academic centres in Montreal, Ottawa, and Toronto.

We analyzed 1001 participants and found that 590 (58.9%) were prescribed one or more usual home medications that could potentially interact with hydroxychloroquine. The most commonly prescribed drug classes with known interactions were anti-diabetic medications (330/1001, 33%), the selective serotonin/norepinephrine reuptake inhibitors (SSRIs/SNRIs) (173/1001, 17.3%), antipsychotics (typical and atypical) (136/1001, 13.6%), and antiarrhythmics, such as digoxin and amiodarone, (64/1001, 6.4%) ( Table 3 ). The most common classes of antidiabetics were insulin 138/1001 (13.8%) and sulfonylureas 90/1001 (9.0%) ( Table   3 ). The most serious interaction identified was a risk of QTc prolongation, torsade de pointes, and sudden death. A common but less severe interaction was a risk of hypoglycemia requiring increased monitoring. Lowering of the seizure threshold and pharmacokinetic interactions leading to increased hydroxychloroquine levels was uncommon.

We then determined how many PIMs (as identified by the MedSafer tool) with known interactions with hydroxychloroquine presented an opportunity to be proactively deprescribed.

Of the 590/1001 (58.9%) of participants who were prescribed a medication that could interact with hydroxychloroquine, 255 patients had the respective medication identified as a PIM, representing 43.2% of all patients with an interacting medication. Some common deprescribing opportunities that were identified included: 1) too high a dose of digoxin for a patient's renal function, 2) antipsychotic use in patients with a known history of delirium or neurocognitive disorder (risk of stroke, falls, confusion), and 3) insulin and sulfonylureas in patients with a history of hypoglycemia and/or tight glycemic control (HgbA1C <7.5%) ( Table 4) .

We prepared recommendations for the management of interacting medications in patients with COVID-19 who may want to receive treatment with hydroxychloroquine if found to be effective. Examples include holding low doses of antipsychotics or antidepressants during therapy, QTc monitoring and electrolyte optimization with continued use of QTc prolonging agents, and glucose monitoring with concurrent diabetes medications. We also highlight medications, such as amiodarone, that cannot be stopped on short notice for inclusion in clinical trials, due to prolonged half-life (Table 2 ).

We re-analyzed data from the MedSafer pilot and found that 1 in 2 older adults with polypharmacy in our cohort have a chronically prescribed medication that could potentially interact with hydroxychloroquine, half of which were PIMs that could be deprescribed. The number of medical conditions and associated polypharmacy of the cohort places them at high risk of complications from COVID-19, but also potentially at risk of harm from treatments. We identified several common drug classes, many of which are also PIMs, that would preclude many older adults from enrolling in a trial. A main finding was that many older adults were taking medications that carry a known risk of prolonging the QTc. This finding should caution against routine prescribing of QTc prolonging COVID-19 treatments outside of a clinical study, as there is real potential for harm. Importantly, more than 50% of interacting drugs were identified as a PIM that could be proactively deprescribed, rendering the person more likely to be eligible for a trial, and increasing the generalizability of study findings to this population.

In this analysis, we chose to focus on a specific drug, hydroxychloroquine. Of note, there is ongoing debate regarding the safety of hydroxychloroquine for treatment of COVID-19 and studies into efficacy are still ongoing. The risks associated with a medication such as hydroxychloroquine are likely higher for older adults with polypharmacy, especially given how common co-administration of QTc prolonging medications is and the prevalence of underlying cardiac conditions. 41 Many patients in our cohort were also overprescribed oral hypoglycemic agents (a1c <7.5% or a history of hypoglycemia), which when co-prescribed with hydroxychloroquine, could increase the risk of hypoglycemia. Older adults may have decreased oral intake as a result of COVID-19 infection and subsequent dehydration, electrolyte disturbances, nausea, and GI upset, which are also common adverse effects of hydroxychloroquine and may further exacerbate severe cardiac dysrhythmias. 42 We have identified medications that may interact with study drugs that could be deprescribed proactively or at the time of treatment (e.g. off-label low dose quetiapine for sleep and agitation). Others, if stopped abruptly, could lead to serious adverse drug withdrawal events or uncomfortable withdrawal symptoms (e.g. methadone or higher doses of SSRIs). 43 Finally, some medications have long half-lives that require weeks to months to safely discontinue in order to avoid interactions, in this case, it may not be possible to stop the medication in time for treatment and thus the risk of interaction will not be reduced (e.g. azithromycin 44 , fluoxetine, and amiodarone). Of note, while there is a risk of potential interactions between medications, this does not necessarily mean there will be any clinical manifestations.

Currently, the use of antimalarials for the treatment or prevention of COVID-19 has extremely limited evidence. 27 If robust evidence demonstrating efficacy in the treatment of COVID-19 is established, some clinicians might opt to continue certain medications that cannot be stopped abruptly, or where symptoms of withdrawal are thought to be significant. In most cases, this would involve judicious monitoring of the QTc and minimizing other risk factors (electrolyte abnormalities, bradycardia). While cardiac monitoring is generally available for hospitalized patients, and perhaps at select nursing homes, this is likely not the case for most outpatients. Finally, it is important to take into consideration the half-life of the treatment medication to know how long symptoms should be monitored for and when it is safe to re-start medications (hydroxychloroquine, range: 20-120 days; mean: 40 days). [45] [46] [47] The risk of QTc prolongation may persist beyond the treatment period and remain clinically relevant for an unclear duration. Of note, the optimal effective does of hydroxychloroquine is not known.

While our referenced study uses a daily dose of 600mg, in practice doses are variable, and some jurisdictions may prescribe lower doses of 400 mg daily, and this may have an impact on the risk of drug interactions and of side effects. The above considerations aside, for medications that are PIMs, their interactions with possible COVID-19 therapies are yet another reason to evaluate these medications for safe deprescribing immediately. 48 Any concern for abrupt discontinuation can be avoided by deprescribing in advance of acute illness. 48 While we used hydroxychloroquine as a test case, this should not be interpreted as an endorsement of the medication. The clinical scenario described herein is not limited to hydroxychloroquine. Other treatments including but not limited to lopinavir-ritonavir, colchicine, and dapsone have also been proposed. These treatments similarly do not have significant evidence to support their use presently, but also carry risks of serious drug-drug interactions. 49, 50 Clinicians may be tempted and indeed are prescribing medications out of desperation to provide patients with some form of treatment for COVID-19, but caution and a rigorous review of possible interactions is warranted, especially in older adults with polypharmacy. Notably, this population will often be underrepresented in clinical trials and even if proven effective, harms may still outweigh benefits for some therapies and an individualized approach should always be taken. Presently, while some medications have shown promise, such as hydroxychloroquine and more recently remdesivir 49 , no medication for the treatment of COVID-19 has been proven to be effective and so we would suggest that outside of a clinical trial, the potential harms of off-label prescribing likely outweigh benefits. In the meantime, it is important that we reduce the number of PIMs patients are taking, as it may facilitate more treatment options once clinical evidence is established.

Strengths of this study include a large cohort of older adults from a multi-site trial with polypharmacy, a thorough review of the literature to outline potential drug interactions, and clear instructions for medication management in the setting of drug interactions. This cohort also reflects the latest FDA recommendation that hydroxychloroquine should not be used outside of a clinical trial or a hospitalized setting. 14 Yet, our study has several limitations. As they were all hospitalized, the patients in this study likely represent those that are most likely to experience harm as a result of widespread prescribing of hydroxychloroquine. Future work should focus on finding safe and effective treatments in long-term care facilities where the burden of polypharmacy is high, there is an increased risk for COVID-19 exposure and effective treatments may decrease the risk of hospitalization. We chose to focus on hydroxychloroquine as a test case in order to provide realistic examples of harm that could result from widespread prescribing; reviewing all potential therapies and their subsequent drug-drug interactions was beyond the scope of this paper. However, similar recommendations could be generated for other potential treatments and may be more complex. For example, interactions with the lopinavir-ritonavir are more extensive than we have outlined for hydroxychloroquine.

Additionally, the clinical significance of the interactions identified vary with cardiac complications, with sudden death being the most severe, whereas absolute risks of seizure or hypoglycemia are less well defined. All patients in our cohort were on at least five medications. This is the case for approximately 50% of older Americans. 24, 25 For those on fewer medications, the risk of drug-drug interactions is less. On the other hand, this study only looked at interactions with home medications. Patients who are hospitalized may have an even higher risk of interactions as they receive additional treatments (e.g. concurrent antibiotics that prolong the QTc, antipsychotics for the management of delirium, insulin etc.). Finally, while the population of patients we analyzed is Canadian, the problem of polypharmacy has been widely described in the United States and countries across the world, so the principles outlined in the discussion can be extrapolated to other jurisdictions.

Polypharmacy has many unpredictable consequences. There are well described harms (e.g. falls, fractures and cognitive impairment) 23 but we describe an emerging concern in the era of COVID-19. Patients may not be eligible for COVID-19 trials to study the effectiveness and safety of the medications under investigation. Others may be subject to harm as a result of offlabel prescribing due to the risk of drug-drug interactions. Now more than ever, we should examine the medication lists of older adults with a focus on medication optimization and stopping PIMs, particularly those which may interact with potential COVID-19 therapies.

We wish to thank the patients who enrolled in the original MedSafer study who agreed to participate in research into polypharmacy Table 2 for potential triggering conditions) **Metformin was not considered to be at risk of causing hypoglycemia for the purposes of this analysis PIM= potentially inappropriate medication; CNS= central nervous system; HCQ=hydroxychloroquine **Fluoxetine has a prolonged half-life of deprescribing needs to take place well in advance (4-6 weeks) of combining with hydroxychloroquine 

World Health Organization. Pneumonia of unknown cause -China. Janurary 5, 2020. 2. World Health Organization

World Health Organization. Rolling updates on coronavirus disease (COVID-19)

COVID-19 Coronavirus Pandemic

National Library of Medicine

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems Close supervision is strongly recommended

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

FDA authorizes widespread use of unproven drugs to treat coronavirus, saying possible benefit outweighs risk

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

COVID-19 Presents High Risk to Older Persons

What is polypharmacy? A systematic review of definitions

Clinical consequences of polypharmacy in elderly

Frequency and Predictors of Polypharmacy in US Medicare Patients: A Cross-Sectional Analysis at the Patient and Physician Levels

Medication Overload: America's Other Drug Problem; How the drive to prescribe is harming older Americans. Lown Institute

Inappropriate prescribing and adverse drug events in older people

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases

Potentially Inappropriate Medications Defined by STOPP Criteria and the Risk of Adverse Drug Events in Older Hospitalized PatientsPIMs Defined by STOPP Criteria and Risk of ADEs

Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals

Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults

Choosing Wisely Canada Recommendations

The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care

STOPP/START criteria for potentially inappropriate prescribing in older people: version 2

Product Monograph Including Patient Medication Information Plaquenil

Hydroxychloroquine Drug Interactions

Fact sheet for health care providers emergency use authorization

Fact sheet for health care providers emergency use authorization (EUA) of Chloroquine Phosphate supplied from the strategic National stockpile for treatment of COVID-19 in certian hospitilized patients

A global clinical measure of fitness and frailty in elderly people

Considerations for Drug Interactions on QTc in Exploratory COVID-19

COVID-19 in Older Adults: Key Points for Emergency Department Providers

Adverse events after discontinuing medications in elderly outpatients

Family of New York woman blames hydroxychloroquine combo for fatal heart attack

Plaquenil Hydroxychloroquine Sulfate Tablets, USP

Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS

Optimizing Medication Management during the COVID-19 Pandemic: Implementation Guide for Post-Acute and Long-Term Care2020

Compassionate Use of Remdesivir for Patients with Severe Covid-19

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

No patients were on the following medication: Thioridazine, Procainamide, Promethazine No patients had the following medication(s) flagged as potentially inappropriate: Venlafaxine *HbA1c: Hemoglobin A1c